Medtronic Gets CE Mark for In.Pact Admiral Drug Eluting Balloon

Dublin, Ireland-based Medtronic plc has received the CE mark designation for its In.Pact Admiral drug eluting balloon (DEB) (also known as the In.Pact Admiral drug-coated balloon (DCB) in non-European markets) for arteriovenous (AV) access to help maintain hemodialysis access in patients with end-stage renal disease.

Globally, more than 2.5 million end-stage renal disease patients are undergoing hemodialysis, a procedure that filters waste and removes extra fluid from the blood when the kidneys are no longer healthy. AV access sites are used to provide hemodialysis to patients. However, thickening of the vessel walls and restenosis, due to repeated access for needed dialysis, can limit the ability to use and eventually shut down the dialysis access site. In.Pact Admiral DEB aids in preventing restenosis, by opening the artery and delivering paclitaxel, an anti-proliferative agent, to the vessel wall. A new 40 cm catheter shaft will also be made commercially available in Europe under the expanded indication, which is specifically designed for AV access. In the United States, In.Pact Admiral DEB is approved to treat superficial femoral and popliteal arteries.

“For patients with hemodialysis, maintaining AV access is their lifeline to receiving the care they need to filter waste from their system. In the past, when the access site became stenosed, the only option was the use of a standard percutaneous transluminal angioplasty (PTA), which can result in the need for repeat procedures,” said Konstantinos Katsanos, M.D., Ph.D., Guy’s and St. Thomas’ Hospital, London, United Kingdom. “The In.Pact Admiral DEB, in my experience, provides a safe and more effective way of managing AV access by preventing vascular restenosis, improving patency of dialysis fistulas and grafts, and reducing the need of repeat PTA procedures.”

“In.Pact Admiral DEB, a best-in-class therapy for the treatment of superficial femoral artery (SFA) disease, is now indicated in Europe for the treatment of AV access, providing a durable primary intervention that aids in extending time to re-intervention while preserving future treatment options,” said Brian Verrier, vice president and general manager of the Peripheral business, within the Aortic and Peripheral Vascular division at Medtronic. “Improving lives and alleviating pain is a core piece of Medtronic’s mission, and through In.Pact Admiral DEB, we can help physicians treat patients with end-stage renal disease.”